Editas Medicine Archives

Home Editas Medicine

Latest Posts

In Depth 11 Feb 2019

CRISPR: One Patent to Rule Them All

The gene editing tool CRISPR-Cas9 has revolutionized research in biology. With several parties fighting for the rights to the technology’s intellectual property, how difficult is it for third parties to…

February 11, 2019 - 5 minutesmins - By Timothé Cynober

In Depth 10 Mar 2021

Can Gene Therapy Cure Blindness?

Since the approval of the first gene therapy for blindness, there has been a wave of companies developing gene therapy treatments with the potential to cure different forms of genetic…

March 10, 2021 - 7 minutesmins - By Clara Rodríguez Fernández

Allergan Editas Medicine CRISPR eye disease

News and Trends 15 Mar 2017

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency…

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Feb 2017

The Patent Office has Spoken: What does it Mean for CRISPR in Europe?

The US Patent Office has ruled that the Broad Institute's CRISPR patents do not interfere with those from UC Berkeley. While this might sound like everybody wins, it’s actually a…

February 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Dec 2016

UPDATE: No Clear Winner in the CRISPR Patent Battle

Today marks an inflection point in the future of medicine: both parties fighting for the ownership of CRISPR have made their oral arguments in front of a jury. Who will win…

December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

How much of a Gamble is Investing in CRISPR?

CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public,…

November 15, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming…

September 12, 2016 - 3 minutesmins - By Evelyn Warner

deskgen desktop genetics biotech labiotech refresh crispr

News and Trends 5 Jul 2016

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

The problem with CRISPR, is that not many people are actually experts in the field, and there are only a select few who worked on it pre-2013. So how did this…

July 5, 2016 - 4 minutesmins - By Dani Bancroft

News and Trends 30 Sep 2015

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

CRISPR is already revolutionizing Biotechnology. However, like every biotech revolution, there then follows a patent war. But the discovery of a new gene editing protein (Cpf1), with the potential of…

September 30, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Sep 2015

Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments

Gene Editing has been made much easier thanks to CRISPR but managing your genome editing workflow can be a challenge. London-based Desktop Genetics wants to solve this problem and just raised…

September 16, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 18 Jun 2015

German Viral Vector Producer SIRION pursues its American dream and opens in Boston

The biggest biocluster of the World is still attractive. Munich-based Sirion Biotech decided to open an office to establish its US presence and benefit from Boston's leading position in the gene therapy…

June 18, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Apr 2015

CRISPR Therapeutics opens Boston R&D Office to Win the CRISPR War

CRISPR Therapeutics appointed Bill Lundberg to Chief Scientific Officer to lead the company’s development programs and to spearhead the creation of its R&D operations in Cambridge, Massachusetts. The biopharmaceutical company…

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering